Study identifies potential RAS inhibitor-immunotherapy strategy for pancreatic cancer

by Dana-Farber Cancer Institute

edited by Lisa Lock, reviewed by Andrew Zinin

Lisa Lock

Scientific Editor

Meet our editorial team
Behind our editorial process

Andrew Zinin

Chief Editor

Meet our editorial team
Behind our editorial process Editors' notes

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

peer-reviewed publication

trusted source

proofread

The GIST Add as preferred source

Pancreatic cancer does not respond to most immunotherapies, but RAS inhibitors could alter tumors to make them more sensitive to a novel immunotherapeutic approach. In pancreatic tumors with RAS mutations, RAS inhibitors cause massive cell death and reduce immunosuppression. These changes tend to be temporary because tumors develop resistance to the therapy.

In a new study, mouse models of pancreatic cancer were treated with a RAS inhibitor plus an agent called 21h10, an AI-designed mimic of an immune-related cytokine called interleukin (IL)-21. The combination initiated an immune response that turned the transient effects of RAS inhibition into a durable response. The work is published in the journal Cell.

The team found that 21h10—which was designed by David Baker's lab at the University of Washington to be more stable and have better drug-like qualities than naturally occurring IL-21—primes and activates CD4 T cells in the cancer. These T cells produce a signal called interferon-γ (IFN-γ), which induces innate immune cells called macrophages to destroy tumor cells.

Previous studies by this team of 21h10 in melanoma and colorectal cancer models also showed efficacy, but in those cases, CD8 T cells acted against the tumors. The findings could be relevant in humans: CD4 T cells from people with pancreatic cancer produced IFN-γ in response to 21h10 in this study, though more research is needed to understand the approach's efficacy and safety.

This study suggests that durable remissions for patients with pancreatic cancer might be possible with a novel combination of immunotherapy and RAS-targeted therapy. Immunotherapies typically focus on the activation of cytotoxic CD8 T cells, but this study suggests that tumor-specific CD4 T cells could control pancreatic cancer by coordinating innate immune cells against the disease when stimulated through IL-21 signaling alongside treatment with a KRAS inhibitor.

Publication details

Li Qiang et al, CD4 T cells convert transient responses to KRAS inhibition to durable remissions in pancreatic cancer, Cell (2026). DOI: 10.1016/j.cell.2026.08.045

Journal information: Cell

Key medical concepts

Pancreatic CancerMacrophages

Clinical categories

OncologyAllergy and immunology Provided by Dana-Farber Cancer Institute Who's behind this story?

Lisa Lock

BA art history, MA material culture. Former museum editor, paramedic, and transplant coordinator. Editing for Science X since 2021. Full profile →

Andrew Zinin

Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →

Citation: Study identifies potential RAS inhibitor-immunotherapy strategy for pancreatic cancer (2026, September 23) retrieved 23 September 2026 from https://medicalxpress.com/news/2026-09-potential-ras-inhibitor-immunotherapy-strategy.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.